J. Matthew Singleton is Director at Viking Therapeutics, Inc. (VKTX). They have made 9 open-market trades across 2 companies since 2008, most recently 2026-01-02.
CIK 0001243514
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $93K since 2018, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VKTX | SELL · 10b5-1 | 2024-10-25 | 2024-10-25 | $79.50 | $1.3M | -16.7% | -34.2% | -55.8% |
| VKTX | SELL · 10b5-1 | 2024-09-20 | 2024-09-20 | $69.50 | $716K | -8.4% | -8.9% | -41.3% |
| VKTX | SELL · 10b5-1 | 2024-08-21 | 2024-08-22 | $69.72 | $397K | -9.3% | +1.5% | -19.5% |
| VKTX | SELL · 10b5-1 | 2024-08-19 | 2024-08-19 | $62.40 | $1.8M | -2.0% | +0.9% | -23.1% |
| VKTX | SELL · 10b5-1 | 2024-08-14 | 2024-08-14 | $57.52 | $2.4M | +12.8% | +14.9% | +4.3% |
| VKTX | BUY | 2018-05-31 | 2018-05-31 | $9.82 | $93K | -3.9% | -5.5% | +13.4% |
| CBST | SELL | 2013-05-22 | 2013-05-22 | $55.48 | $1.5M | N/A | N/A | N/A |
| CBST | SELL | 2012-08-24 | 2012-08-27 | $45.52 | $114K | N/A | N/A | N/A |
| CBST | SELL | 2012-03-09 | 2012-03-12 | $43.06 | $431K | N/A | N/A | N/A |
| CBST | SELL | 2012-02-03 | 2012-02-06 | $42.28 | $85K | N/A | N/A | N/A |
| CBST | SELL | 2009-01-14 | 2009-01-15 | $22.76 | $46K | N/A | N/A | N/A |
| CBST | SELL | 2008-12-17 | 2008-12-18 | $23.66 | $47K | N/A | N/A | N/A |
| CBST | SELL | 2008-11-19 | 2008-11-20 | $22.78 | $46K | N/A | N/A | N/A |
| CBST | SELL | 2008-10-29 | 2008-10-30 | $21.60 | $43K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.